An anti-HIV combination pill should be approved to prevent HIV infection in healthy people, an FDA advisory committee agreed overwhelmingly Thursday.
The combination of emtricitabine and tenofovir (Truvada) is safe and well tolerated, the committee decided, and helps prevent HIV infection when used daily by people at high risk.
The panel voted 19-3 that a risk-benefit analysis favored approval of the drug for men who have sex with men, and 19-2, with one abstention, for heterosexuals in couples in which one partner has HIV and the other does not.
Read the full story: http://hcp.lv/K2EONW
Source: MedPage Today